Autoimmune Encephalitis (AE)O-MEG-A-MINDNCT07689682
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
A study testing OPM- Magnetoencephalography in people with Autoimmune Encephalitis (AE) and Acute Disseminated Encephalomyelitis, run by Aston University at 2 sites in United Kingdom.
Trial summary
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. Read more about this study
- Who is it for?
- Ages 2 to 16 yearsHealthy volunteers can take part
- Conditions the study is for
- Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- What is being tested?
- OPM- Magnetoencephalography
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 15 May 2026to 15 Sep 2034
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 16 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g. autoimmune encephalitis1, acute disseminated encephalomyelitis, multiple sclerosis. 2
- Individuals who have received a diagnosis of a non-immune mediated neurological disease (age range 2 yrs to 15 years 11 months) e.g. stroke.
- Patients who can give informed consent/ assent and have a person with parental responsibility capable of giving informed consent on their behalf if aged <16 years.
Who cannot join
- There is metal in the body or any other contraindication that precludes MRI scanning at IHN, or child usually requires sedation for clinical MRI scans.
- Participant dissents.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom2 sites, 2 recruiting
- Recruiting
Birmingham Children's Hospital
Birmingham, West Midlands, B4 6NH
Sukhvir Wright, 07973352814, sukhewright@gmail.com
- Recruiting
Aston University
Birmingham
Matt Richards, +44 121 204 5069, m.richards3@aston.ac.uk
About this study
Official title: The "O-MEG-A-MIND" Study OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. But even with better treatments, many patients-especially children-still struggle with long-term problems. Standard brain scans and tests often miss important issues like memory problems, emotional difficulties, trouble sleeping, and challenges with social behaviour. Early research using a special brain imaging technique (called MEG) has shown changes in brain networks that seem to be linked to poor memory. This study will use a new, advanced version of MEG that works even with very young children (as young as 2 years old). The goal is to better understand how these brain conditions affect children, compare them with other types of brain illness, and eventually use this technology to help predict outcomes and discover new ways to track brain health.
Read the detailed description
This study is an 8-year cross-sectional and observational cohort study involving the use of OPM-MEG, MEG, MRI and neuropsychology testing based at the Aston Institute of Health and Neurodevelopment, Birmingham, UK. Children and young people with immune and non-immune mediated neurological disease aged 2-15 years will be recruited locally (Birmingham Children's Hospital) and from London and Manchester.
The longitudinal cohorts (n=25 in each, total n=50) will be those with immune- and non-immune mediated neurological disease within 9 months of diagnosis. They will be invited for 3 study visits (Study Visits 1, 2 and 3).
The cross-sectional cohort (n=25) will be those with immune-mediated neurological disease at least 18 months after diagnosis. They will be invited to for one study visit (Study Visit 1).
The study visits:
At Study Visit 1 (Baseline), participants will undergo OPM-MEG, MEG and MRI as well as neuropsychology testing and questionnaire completion. Total time taken is 5 hours. This visit can be split into 2 visits within a 2 week window.
At Study Visit 2 (2 years)and 3 (5 years) participants will undergo OPM-MEG, MEG and MRI and questionnaire completion. Total time taken is 3 hours.
Participants travelling from outside the West Midlands will be offered overnight accommodation for Study Visits.
The participants are welcome to have as many breaks as is necessary during each/any Study Visit. It is expected that breaks will last between 15 minutes to one hour. Refreshments will be available for the participants on the day and will ask in advance of the visit in case of any allergies. Aston University, where the IHN is based, has food outlets Tesco, Greggs and Costa Coffee available too. Another adult, aside from the research team, can be present during the research recordings.
- Being tested
- OPM- Magnetoencephalography
- Keywords
- neuroimaging, autoimmune encephalitis, ADEM, magnetoencephalography, OPM-MEG
- Medical subject headings
- Autoimmune Diseases of the Nervous System, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OPM- MagnetoencephalographyDevice
Also called MRI, neuropsychology assessment
To assess the changes in brain network function that occur in relation to immune and non-immune mediated brain disease, participants will undergo OPM-MEG recording. This will be conducted at all study visits.
To assess the behavioural and functional changes following disease from the patient and caregiver perspective questionnaires will be completed on paper-based forms. These are all established outcomes measures used in our and others' previous studies in immune and non-immune mediated disease in children.
The cryogenic MEG recording will also assess changes in brain dysfunction and will be directly comparable to the advanced OPM-MEG data.
To assess the effect of disease on brain structures, participants will undergo MRI scanning at the IHN.
To assess functional outcomes of immune and non-immune mediated disease, participants will undergo neuropsychology assessments.
| Study group | Role | What they receive |
|---|---|---|
| Cross-sectional - participants who have had a neuroimmunological condition over 18 months ago | Experimental | Longitudinal - participants who are within 9 months of disease Receives: Device: OPM- Magnetoencephalography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of group differences over time in imaging metrics using OPM-MEG.
Change from Baseline in OPM-MEG Resting-State Delta-Band (1-4 Hz) Local Efficiency
Local efficiency of resting-state brain networks derived from OPM-MEG recordings, computed from amplitude envelope correlation connectivity matrices (Desikan-Killiany atlas parcellation) using the Brain Connectivity Toolbox, compared between participants with immune-mediated and non-immune-mediated neurological disease across proportional connectivity thresholds (10-30%).
Measured: Baseline (Study Visit 1), 2 years (Study Visit 2), 5 years (Study Visit 3)
Secondary outcomes (3)
Change from Baseline in Whole-Brain Cortical Thickness
Mean cortical thickness across the whole brain, measured from T1-weighted MRI using FreeSurfer surface-based analysis, compared between disease groups.
Measured: Baseline, 2 years, 5 years
Correlation Between Resting-State Network Graph Measures and Wechsler Working Memory Index Score
Association between OPM-MEG/MEG-derived delta and theta local efficiency, global efficiency, and modularity values (particularly theta modularity) and Working Memory Index composite scores from the Wechsler Intelligence Scale for Children - Fifth Edition and the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition (WISC-V/WPPSI-4), analyzed by multiple regression controlling for sex. On the WISC-V and WPPSI-IV, the theoretical minimum Full Scale IQ score is 40 and the maximum score is 160, with higher scores indicating better cognitive outcomes and stronger academic potential.
Measured: Baseline, 2 years, 5 years
Diagnostic/Predictive Performance of Imaging Metrics for Clinical Outcome Group (mRS-Defined)
Sensitivity/specificity or area-under-curve of OPM-MEG, MEG, and MRI-derived metrics (local efficiency, modularity, cortical thickness) for classifying participants by modified Rankin Scale outcome category at follow-up.
Measured: 2 years, 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start15 May 2026
- Primary completion15 Sep 2034 (estimated)
- Study completion15 Sep 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Autoimmune Encephalitis (AE)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is an 8-year cross-sectional and longitudinal prospective repeated measures observational study.
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aston University
- Sponsor type
- University, hospital or other
- Collaborators
- Birmingham Children's Hospital, United Kingdom
- Responsible party
- Sponsor
- Investigators
- Sukhvir Wright, Principal investigator, Aston University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07689682
- Sponsor's protocol ID
- 356138
- Other IDs
- 311141/Z/24/Z
- Acronym
- O-MEG-A-MIND
- Status last verified
- Oct 2026
- First submitted
- 25 Jun 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data from this cohort may be highly valuable to future research efforts. Thus, we will ask participants to provide written informed consent to make their anonymised data freely available for reanalysis by the team in future studies, and to researchers outside of the study team for use in ethically approved projects. Specifically, neuroimaging (MRI), questionnaire, neuropsychology (summary scores) and demographic data that are suitable for sharing will be made available, using open-access data repositories platforms such as OSF (osf.org) or other suitable platforms which meet current best practice within the field, in relation to local and national regulations (i.e. GDPR). Open-access sharing of data will only happen once the linking document (linking study ID to personal identifiable data i.e. name) is destroyed (3 years after study end), to ensure that shared data is truly anonymous, not pseudo-anonymised
Publications
Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M; International NMDAR Antibody Encephalitis Consensus Group; Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostasy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Nov 1;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188.
PubMed 34542573Billaud CHA, Wood AG, Griffiths-King D, Kessler K, Wassmer E, Foley E, Wright SK. Examining cognition and brain networks using magnetoencephalography in paediatric autoimmune encephalitis and acute disseminated encephalomyelitis: a preliminary study. Brain Commun. 2024 Aug 8;6(4):fcae248. doi: 10.1093/braincomms/fcae248. eCollection 2024.
PubMed 39130516
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The "O-MEG-A-MIND" Study OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
- ClinicalTrials.gov ID
- NCT07689682
- Acronym / sponsor ID
- O-MEG-A-MIND / 356138
- Keywords
- neuroimaging, autoimmune encephalitis, ADEM, magnetoencephalography, OPM-MEG
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Aston UniversityUniversity, hospital or other
- Collaborators
- Birmingham Children's Hospital, United Kingdom
- Study start
- 15 May 2026 (actual)
- Primary completion
- 15 Sep 2034 (estimated)
- Study completion
- 15 Sep 2034 (estimated)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. But even with better treatments, many patients-especially children-still struggle with long-term problems. Standard brain scans and tests often miss important issues like memory problems, emotional difficulties, trouble sleeping, and challenges with social behaviour. Early research using a special brain imaging technique (called MEG) has shown changes in brain networks that seem to be linked to poor memory. This study will use a new, advanced version of MEG that works even with very young children (as young as 2 years old). The goal is to better understand how these brain conditions affect children, compare them with other types of brain illness, and eventually use this technology to help predict outcomes and discover new ways to track brain health.
Detailed description
This study is an 8-year cross-sectional and observational cohort study involving the use of OPM-MEG, MEG, MRI and neuropsychology testing based at the Aston Institute of Health and Neurodevelopment, Birmingham, UK. Children and young people with immune and non-immune mediated neurological disease aged 2-15 years will be recruited locally (Birmingham Children's Hospital) and from London and Manchester.
The longitudinal cohorts (n=25 in each, total n=50) will be those with immune- and non-immune mediated neurological disease within 9 months of diagnosis. They will be invited for 3 study visits (Study Visits 1, 2 and 3).
The cross-sectional cohort (n=25) will be those with immune-mediated neurological disease at least 18 months after diagnosis. They will be invited to for one study visit (Study Visit 1).
The study visits:
At Study Visit 1 (Baseline), participants will undergo OPM-MEG, MEG and MRI as well as neuropsychology testing and questionnaire completion. Total time taken is 5 hours. This visit can be split into 2 visits within a 2 week window.
At Study Visit 2 (2 years)and 3 (5 years) participants will undergo OPM-MEG, MEG and MRI and questionnaire completion. Total time taken is 3 hours.
Participants travelling from outside the West Midlands will be offered overnight accommodation for Study Visits.
The participants are welcome to have as many breaks as is necessary during each/any Study Visit. It is expected that breaks will last between 15 minutes to one hour. Refreshments will be available for the participants on the day and will ask in advance of the visit in case of any allergies. Aston University, where the IHN is based, has food outlets Tesco, Greggs and Costa Coffee available too. Another adult, aside from the research team, can be present during the research recordings.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is an 8-year cross-sectional and longitudinal prospective repeated measures observational study.
| Arm | Type | Receives |
|---|---|---|
| Cross-sectional - participants who have had a neuroimmunological condition over 18 months ago | Experimental | Device: OPM- MagnetoencephalographyLongitudinal - participants who are within 9 months of disease |
Who may qualify
- Ages
- 2 to 16 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g. autoimmune encephalitis1, acute disseminated encephalomyelitis, multiple sclerosis. 2
- Individuals who have received a diagnosis of a non-immune mediated neurological disease (age range 2 yrs to 15 years 11 months) e.g. stroke.
- Patients who can give informed consent/ assent and have a person with parental responsibility capable of giving informed consent on their behalf if aged <16 years.
Key exclusion criteria (2 listed)
- There is metal in the body or any other contraindication that precludes MRI scanning at IHN, or child usually requires sedation for clinical MRI scans.
- Participant dissents.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OPM- MagnetoencephalographyAlso: MRI, neuropsychology assessmentTo assess the changes in brain network function that occur in relation to immune and non-immune mediated brain disease, participants will undergo OPM-MEG recording. This will be conducted at all study visits. To assess the behavioural and functional changes following disease from the patient and caregiver perspective questionnaires will be completed on paper-based forms. These are all established outcomes measures used in our and others' previous studies in immune and non-immune mediated disease in children. The cryogenic MEG recording will also assess changes in brain dysfunction and will be directly comparable to the advanced OPM-MEG data. To assess the effect of disease on brain structures, participants will undergo MRI scanning at the IHN. To assess functional outcomes of immune and non-immune mediated disease, participants will undergo neuropsychology assessments. | Device | Cross-sectional - participants who have had a neuroimmunological condition over 18 months ago |
Primary outcome
Detection of group differences over time in imaging metrics using OPM-MEG.
Time frame: Baseline (Study Visit 1), 2 years (Study Visit 2), 5 years (Study Visit 3)
Change from Baseline in OPM-MEG Resting-State Delta-Band (1-4 Hz) Local Efficiency Local efficiency of resting-state brain networks derived from OPM-MEG recordings, computed from amplitude envelope correlation connectivity matrices (Desikan-Killiany atlas parcellation) using the Brain Connectivity Toolbox, compared between participants with immune-mediated and non-immune-mediated neurological disease across proportional connectivity thresholds (10-30%).
3 secondary outcomes
Change from Baseline in Whole-Brain Cortical Thickness
Time frame: Baseline, 2 years, 5 years
Correlation Between Resting-State Network Graph Measures and Wechsler Working Memory Index Score
Time frame: Baseline, 2 years, 5 years
Diagnostic/Predictive Performance of Imaging Metrics for Clinical Outcome Group (mRS-Defined)
Time frame: 2 years, 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Background: PubMed 34542573Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M; International NMDAR Antibody Encephalitis Consensus Group; Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostasy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Nov 1;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188.
- Background: PubMed 39130516Billaud CHA, Wood AG, Griffiths-King D, Kessler K, Wassmer E, Foley E, Wright SK. Examining cognition and brain networks using magnetoencephalography in paediatric autoimmune encephalitis and acute disseminated encephalomyelitis: a preliminary study. Brain Commun. 2024 Aug 8;6(4):fcae248. doi: 10.1093/braincomms/fcae248. eCollection 2024.
- Individual participant dataSharing planned: Yes. Data from this cohort may be highly valuable to future research efforts. Thus, we will ask participants to provide written informed consent to make their anonymised data freely available for reanalysis by the team in future studies, and to researchers outside of the study team for use in ethically approved projects. Specifically, neuroimaging (MRI), questionnaire, neuropsychology (summary scores) and demographic data that are suitable for sharing will be made available, using open-access data repositories platforms such as OSF (osf.org) or other suitable platforms which meet current best practice within the field, in relation to local and national regulations (i.e. GDPR). Open-access sharing of data will only happen once the linking document (linking study ID to personal identifiable data i.e. name) is destroyed (3 years after study end), to ensure that shared data is truly anonymous, not pseudo-anonymised
Related trials for Autoimmune Encephalitis (AE)
Recruiting
Plasma Exchange in Pediatric Autoimmune Encephalitis
Autoimmune Encephalitis (AE)
Not yet recruitingPhase 2
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
Autoimmune Encephalitis (AE)
Not yet recruitingPhase 4
Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Autoimmune Encephalitis (AE), Autoimmune Cerebellitis
RecruitingPhase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
RecruitingEarly Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sukhvir Wright principal investigator
Aston University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing OPM- Magnetoencephalography in people with Autoimmune Encephalitis (AE) and Acute Disseminated Encephalomyelitis, run by Aston University at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sukhvir Wright, MBBS, DPhil (+44 121 204 3076, omegamind@aston.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of group differences over time in imaging metrics using OPM-MEG. (time frame: Baseline (Study Visit 1), 2 years (Study Visit 2), 5 years (Study Visit 3)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07689682, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.